Lonza Group Ag EBITDA 2012-2024 | LZAGY
Lonza Group Ag annual and quarterly EBITDA history from 2012 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Lonza Group Ag EBITDA for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Lonza Group Ag EBITDA for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Lonza Group Ag 2023 annual EBITDA was $1.229B, a 41.29% decline from 2022.
- Lonza Group Ag 2022 annual EBITDA was $2.093B, a 49.54% increase from 2021.
- Lonza Group Ag 2021 annual EBITDA was $1.399B, a 4.93% decline from 2020.
| Lonza Group Ag Annual EBITDA (Millions of US $) |
|
|---|---|
| 2023 | $1,229 |
| 2022 | $2,093 |
| 2021 | $1,399 |
| 2020 | $1,472 |
| 2019 | $1,526 |
| 2017 | $1,152 |
| 2016 | $805 |
| 2015 | $445 |
| 2014 | $790 |
| 2013 | $607 |
| 2012 | $682 |
| 2011 | $608 |
| Lonza Group Ag Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2024-12-31 | |
| 2023-12-31 | |
| 2023-06-30 | |
| 2022-12-31 | |
| 2022-06-30 | |
| 2021-12-31 | |
| 2021-06-30 | |
| 2020-12-31 | |
| 2020-06-30 | |
| 2019-12-31 | |
| 2019-06-30 | |
| 2018-12-31 | |
| 2018-06-30 | |
| 2017-12-31 | |
| 2017-06-30 | |
| 2016-12-31 | |
| 2016-06-30 | |
| 2015-12-31 | |
| 2015-06-30 | |
| 2014-12-31 | |
| 2014-06-30 | |
| 2013-12-31 | |
| 2013-06-30 | |
| 2012-12-31 | |
| 2012-06-30 | |
| 2011-12-31 | |
| 2011-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $51.237B | $7.468B |
| Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company's Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $152.324B | 38.13 |
| Stryker (SYK) | United States | $149.641B | 31.29 |
| EssilorLuxottica (ESLOY) | France | $137.721B | 0.00 |
| Medtronic (MDT) | Ireland | $114.146B | 16.18 |
| Haleon (HLN) | United Kingdom | $45.147B | 25.77 |
| ResMed (RMD) | United States | $37.534B | 28.19 |
| GE HealthCare Technologies (GEHC) | United States | $34.575B | 16.42 |
| Agilent Technologies (A) | United States | $34.457B | 22.46 |
| Terumo (TRUMY) | Japan | $25.051B | 32.54 |
| Koninklijke Philips (PHG) | Netherlands | $23.235B | 16.30 |
| Insulet (PODD) | United States | $20.934B | 82.17 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.835B | 12.10 |
| Baxter (BAX) | United States | $15.298B | 11.42 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.441B | 0.00 |
| Demant (WILYY) | Denmark | $8.971B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.887B | 23.97 |
| Lantheus Holdings (LNTH) | United States | $5.776B | 14.57 |
| Prestige Consumer Healthcare (PBH) | United States | $3.897B | 17.41 |
| Perrigo (PRGO) | Ireland | $3.742B | 9.48 |
| Haemonetics (HAE) | United States | $3.724B | 16.96 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.454B | 28.70 |
| ICU Medical (ICUI) | United States | $3.341B | 24.63 |
| QuidelOrtho (QDEL) | United States | $2.135B | 14.68 |
| LeMaitre Vascular (LMAT) | United States | $1.910B | 42.70 |
| AtriCure (ATRC) | United States | $1.580B | 0.00 |
| Acuren (TIC) | United States | $1.397B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.272B | 16.26 |
| Green Thumb Industries (GTBIF) | United States | $1.249B | 28.09 |
| AdaptHealth (AHCO) | United States | $1.247B | 12.66 |
| Neogen (NEOG) | United States | $1.194B | 15.28 |
| BioLife Solutions (BLFS) | United States | $1.068B | 0.00 |
| InMode (INMD) | Israel | $0.963B | 9.70 |
| Kestra Medical Technologies (KMTS) | United States | $0.791B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.703B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.679B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.670B | 0.00 |
| Owens & Minor (OMI) | United States | $0.667B | 5.53 |
| Evolus (EOLS) | United States | $0.623B | 0.00 |
| CeriBell (CBLL) | United States | $0.596B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.522B | 0.00 |
| Valneva SE (VALN) | France | $0.502B | 0.00 |
| Surmodics (SRDX) | United States | $0.441B | 0.00 |
| SNDL (SNDL) | Canada | $0.373B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.347B | 12.77 |
| Sanuwave Health (SNWV) | United States | $0.308B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Quanterix (QTRX) | United States | $0.295B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.291B | 0.00 |
| Cerus (CERS) | United States | $0.285B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.276B | 23.27 |
| Sanara MedTech (SMTI) | United States | $0.269B | 0.00 |
| ZimVie (ZIMV) | United States | $0.264B | 12.01 |
| Brainsway (BWAY) | Israel | $0.246B | 65.00 |
| Canopy Growth (CGC) | Canada | $0.232B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.227B | 0.00 |
| Biote (BTMD) | United States | $0.225B | 6.34 |
| Verano Holdings (VRNOF) | United States | $0.210B | 0.00 |
| Omeros (OMER) | United States | $0.198B | 0.00 |
| Organigram Global (OGI) | Canada | $0.193B | 0.00 |
| High Tide (HITI) | Canada | $0.190B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.190B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.186B | 15.15 |
| Vireo Growth (VREOF) | United States | $0.150B | 0.00 |
| Exagen (XGN) | United States | $0.145B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.126B | 15.53 |
| TerrAscend (TSNDF) | Canada | $0.104B | 0.00 |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 12.37 |
| Jin Medical (ZJYL) | China | $0.093B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Apyx Medical (APYX) | United States | $0.086B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.082B | 0.00 |
| Veru (VERU) | United States | $0.081B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.072B | 0.00 |
| Zynex (ZYXI) | United States | $0.072B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| Agape ATP (ATPC) | $0.071B | 0.00 | |
| Cytosorbents (CTSO) | United States | $0.070B | 0.00 |
| ImmuCell (ICCC) | United States | $0.061B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.041B | 0.00 |
| Nephros (NEPH) | United States | $0.040B | 53.29 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 12.82 |
| Safety Shot (SHOT) | United States | $0.033B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.021B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |